Pharmacy data in epidemiological studies: an easy to obtain and reliable tool

Monster, Tbm; Janssen, Wmt; Jong, PE de; Berg, Ltw de Jong-van den

doi:10.1002/pds.722

Cited by 103 publications

(93 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In each screening, the participants underwent two outpatient visits to assess medical history, anthropometry and cardiovascular and metabolic risk factors, and they collected two 24 h urine samples. Information on use of medication was completed and confirmed by using data from pharmacy registries of all community pharmacies in the city of Groningen [19]. In 89.9% of all participants, blood samples for measurement of copeptin were taken after overnight fasting.…”

Section: Methodsmentioning

confidence: 99%

Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study

et al. 2012

View full text Add to dashboard Cite

Aims/hypothesis Vasopressin plays a role in osmoregulation, glucose homeostasis and inflammation. Therefore, plasma copeptin, the stable C-terminal portion of the precursor of vasopressin, has strong potential as a biomarker for the cardiometabolic syndrome and diabetes. Previous results were contradictory, which may be explained by differences between men and women in responsiveness of the vasopressin system. The aim of this study was to evaluate the usefulness of copeptin for prediction of future type 2 diabetes in men and women separately. Methods From the Prevention of Renal and Vascular Endstage Disease (PREVEND) study, 4,063 women and 3,909 men without diabetes at baseline were included. A total of 208 women and 288 men developed diabetes during a median follow-up of 7.7 years. Results In multivariable-adjusted models, we observed a stronger association of copeptin with risk of future diabetes in women (OR 1.49 [95% CI 1.24, 1.79]) than in men (OR 1.01 [95% CI 0.85, 1.19]) (p interaction <0.01). The addition of copeptin to the Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) clinical model improved the discriminative value (C-statistic,+0.007, p00.02) and reclassification (integrated discrimination improvement [IDI] 0 0.004, p<0.01) in women. However, we observed no improvement in men. The additive value of copeptin in women was maintained when other independent predictors, such as glucose, high sensitivity C-reactive protein (hs-CRP) and 24 h urinary albumin excretion (UAE), were included in the model. Conclusions/interpretation The association of plasma copeptin with the risk of developing diabetes was stronger in women than in men. Plasma copeptin alone, and along with existing biomarkers (glucose, hs-CRP and UAE), significantly improved the risk prediction for diabetes in women.

show abstract

Section: Methodsmentioning

confidence: 99%

Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study

et al. 2012

View full text Add to dashboard Cite

show abstract

“…8,9 Misclassification of exposure because of hospitalization before the index date was ignorable. Misclassification of the outcome was a concern in our study as there is no information on the overall PPV of the discharge diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Withdrawal of Statins and Risk of Subarachnoid Hemorrhage

Risselada

Straatman

Kooten

et al. 2009

Stroke

View full text Add to dashboard Cite

show abstract

“…The database records longitudinal drug prescriptions records from more than 50 community pharmacies in The Netherlands, covering a population of 500 000 people since 1999. The number of children aged 0-18 years in this population was approximately 123 000 in 2008 [11,12].…”

Section: Uk: Ims Disease Analysermentioning

confidence: 95%

Comparison of anti‐diabetic drug prescribing in children and adolescents in seven European countries

Neubert

Hsia

Berg

et al. 2011

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The incidence of both type 1 and type 2 diabetes is rising among children and adolescents.• Data on the prevalence of type 1 and type 2 diabetes are limited.• Routine clinical databases can be used to study the prevalence and epidemiology of treatment, depending on the completeness of data capture and their representativeness of the whole population.WHAT THIS STUDY ADDS• The prevalence of insulin prescribing appears to vary among countries, being highest in Sweden (3.5 per 1000 population) and lowest in Italy (1.1 per 1000 population).• The prevalence of oral anti‐diabetic prescribing ranges from 0.08 per 1000 population in Sweden and Germany to 0.21 per 1000 population in the UK; however, the total number of patients receiving oral anti‐diabetics is low.• It is possible to use the same study protocol across clinical databases in Europe to study the prevalence of type 1 diabetes in children.• Routine clinical databases can identify the prevalence of type 1 diabetes prescribing and could be used to study the secular changes in disease prevalence in children.AIMS The aim of this study was to compare the prevalence of diabetes in children across seven European countries, when using prescribing of anti‐diabetics as a proxy for diabetes. A secondary aim was to assess the potential for collaboration between countries using different databases in diabetes research.METHODS Data were obtained from population‐based clinical databases in seven European countries. The study population comprised children aged 0–18 years. Prescriptions were categorized using the Anatomic Therapeutic Chemical (ATC) classification. The one‐year user prevalence in 2008 was calculated for each country and stratified by age and sex.RESULTS We studied a total of 5.8 million children and adolescents. The prevalence of insulin prescribing varied between 1.1 and 3.5 per 1000 population, being highest in Sweden and lowest in Italy. In all countries, novel insulin analogues were the most commonly used insulins. The prevalence of oral anti‐diabetic prescribing ranged from 0.08 per 1000 individuals in Sweden and Germany to 0.21 per 1000 population in the UK. Overall, the absolute number of oral anti‐diabetic users was very low.CONCLUSION This study shows that there is a varying frequency of type 1 diabetes in children and adolescents across Europe. We also demonstrated that it is possible to obtain similar information from different clinical databases within Europe, which would allow continuous monitoring of type 1 diabetes. Owing to the lack of indications in most of the databases, this approach is less suitable for type 2 diabetes.

show abstract

Pharmacy data in epidemiological studies: an easy to obtain and reliable tool

Cited by 103 publications

References 15 publications

Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study

Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study

Withdrawal of Statins and Risk of Subarachnoid Hemorrhage

Comparison of anti‐diabetic drug prescribing in children and adolescents in seven European countries

Contact Info

Product

Resources

About